Hafif-orta şiddetli akne vulgaris yüz tutulumu tedavisinde nadifloksasinin tek başına ve benzoil peroksit ile birlikte kullanımının karşılaştırılması
Amaç: Hafif-orta şiddetli akne vulgaris tedavisinde nadifloksasin kremin tek başına veya benzoil peroksit ile birlikte kullanımının etkinliğini karşılaştırma. Hastalar ve Yöntem: Çift kör, randomize çalışma, toplam 93 hasta 2 grup olarak ya nadifloksasin kremi ya benzoil peroksit losyonun baz formu ya da benzoil peroksit ile birlikte 8 hafta süre ile kullandı. Bulgular: İnflamatuar lezyonlar tek başına nadifloksasin kullanan grupta(n=46) %22, 08, nadifloksasin+benzoil peroksit kullanan grupta(n=47) %53,5 oranında azaldı. Tek başına nadifloksasin kullanan grupta beş (%10,9), nadifloksasin+benzoil peroksit kullanan grupta 18(%38,3)hastada inflamatuar lezyonlarda %50 ve üzeri azalma görüldü. Sonuç: Her iki tedavi de istatistiksel olarak etkili bulundu ancak nadifloksasin+benzoil peroksit grubunda belirgin olarak inflamatuar lezyonlarda azalma görüldü. Her iki tedavi de hafif yan etkiler ile çok iyi tolere edildi
-
Objective: To compare the efficacy of nadifloxacin alone and with benzoyl peroxide in the treatment of mild to moderate facial acne vulgaris. Patients and Methods: This double-blind, randomized study was conducted in a total of 93 acne patients, with at least 10 inflammatory lesions, but no more than 3 nodules or cysts on the face. All patients were instructed to apply nadifloxacin 1% cream twice daily and randomized to apply either benzoyl peroxide 5% lotion or its vehicle once daily for 8 weeks. Results: The mean percent reduction in inflammatory lesions were 22.08% in the nadifloxacin group (n=46) and 53.5% in the nadifloxacin+benzoyl peroxide group (n=47). Five (10.9%) patients in the nadifloxacin group and 18 (38.3%) patients in the nadifloxacin+benzoyl peroxide group achieved a 50% and greater reduction in the inflammatory lesion count. Conclusion: Both treatment regimens were statistically effective, but a significantly greater reduction of the inflammatory lesions was seen in the nadifloxacin+benzoyl peroxide group. The number of patients who achieved a 50% and greater reduction in inflammatory lesion count was significantly higher in the nadifloxacin+benzoyl peroxide group. Both treatment regimens were well tolerated with mild side effects
___
- 1. Thiboutat D, Gollnick H, Bettoli V, et al. New insights into the managements of acne: an update from the Global Alliance to improve outcomes in acne group. J Am Acad Dermatol 2009; 60 (5 Suppl): S1- 50. doi: 10.1016/j.jaad.2009.01.019
- 2. Gollnick H, Cunliffe W, Berson D, et al. Global alliance to improve outcomes in acne. J Am Acad Dermatol 2003; 49 (1 Suppl): S1-37.
- 3. Ross JI, Snelling AM, Eady EA, et al. Phenotypic and genotypic characterization of antibiotic-resistant Propionibacterium acnes isolated from acne patients attending dermatology clinics in Europe, the U.S.A., Japan and Australia. Br J Dermatol 2001; 144: 339-46. doi:10.1046/j.1365-2133.2001.03956.x
- 4. Leyden J, Levy S. The development of antibiotic resistance in Propionibacterium acnes in acne. Cutis 2001; 67 (2 suppl): 21-4.
- 5. Coates P, Vyakrnam S, Eady EA, et al. Prevelance of antibiotic-resistant propionibacteria on the skin of acne patients: 10-year surveillance data and snapshot distrubution study. Br J Dermatol 2002; 146: 840-8. doi:10.1046/j.1365-2133.2002.04690.x
- 6. Kawabata S, Ohguro K, Mukai F, et al. Bacteriological evaluation of OPC-7251, a new pyridone carboxylic acid antimicrobial agent. 1: In vitro antibacterial activity. Chemotherapy 1989; 37: 1160-78.
- 7. Kurukawa I, Akamatsu H, Nishijima S, et al. Clinical and bacteriologic evalution of OPC-7251 in patients with acne: a double-blind group comparison study versus cream base. J am Acad Dermatol 1991; 25: 674-81.
- 8. Jung JY, Kwan HH, Yeau KB, et al. Clinical and histological evalution of 1% nadifloxacin cream in the treatment of acne vulgaris in Korean patients. Int J Dermatol 2011; 50:350-7. doi:10.1111/j.1365- 4632.2010.04701.x
- 9. Plewig G, Holland KT, Nenoff P. Clinical and bacteriological evaluation of nadifloxacin 1% cream in patients with acne vulgaris: a doubleblind, phase 3 comparison study versus erythromycin 2% cream. Eur J Dermatol 2006; 16 : 48-55. doi:10.1586/17469872.1.5.643
- 10. Tunca M, Akar A, Ozmen I, et al. Topical nadifloxacin 1% cream vs. topical erythromycin 4% jel in the treatment of mild to moderate acne. Int J Dermatol 2010; 45:1440-4. doi:10.1111/j.1365- 4632.2010.04601.x
- 11. Bojar RA, Hittel N, Cunliffe WJ, et al. Direct analysis of resistance in the cutaneous microflora during treatment of acne vulgaris with topical 1% nadifloxacin and 2% erythromycin. Drugs 1995; 49 (Suppl 2): 164- 7.
- 12. Alba V, Urban E, Dominguez A, et al. In vitro activity of nadifloxacin against several Gram-positive bacteria and analsis of the possible evalution of resistance after 2 years of use in Germany. Int J Antimicrob Agent 2009; 33: 272-5. doi:10.1016/j.ijantimicag.2008.08.024
- 13. Thiboutat D, Zaenglein A, Weiss J, et al. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: Assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol 2008; 6: 1-9.
- 14. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, doubleblind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006, 54: 73-81. doi:10.1016/j.jaad.2005.04.046
- 15. Simonart T, Dramaix M. Treatment of acne with topical antibiotics: lessons from clinical studies. Br J Dermatol 2005; 153: 395-403.
- 16. Eady EA, Cove JH, Joanes DN. Topical antibiotics for the treatment of acne vulgaris: a critical evaluation of literature on their clinical benefit and comparative efficacy. J Dermatolog Treat 1990; 1: 215-26. doi:10.3109/09546639009086737
- 17. Thiboutot D, Weiss J, Bucko A, Jones T. Adapalene-benzoyl peroxide, a fixed dose combination for the treatment of acne vulgaris: results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol 2007; 57: 791-9. doi:10.1016/j.jaad.2007.06.006
- 18. Cunliffe WJ, Holland KT, Bojar R. A randomized, double-blind comparison of a clindamycin phosphate/benzoyl peroxide gel formulation and a matching clindamycin gel with respect to microbiologic activity and clinical efficacy in the topical treatment of acne vulgaris. Clin Ther 2002; 24: 1117-33. doi:10.1016/S0149- 2918(02)80023-6
- 19. Ozolins M, Eady EA, Avery A, Cunliffe WJ. Comparison of five antimicrobial regimens for the treatment of mild to moderate inflammatory facial acne vulgaris in the community: randomized controlled trial. Lancet 2004; 364: 2188-95. doi:10.1016/S0140- 6736(04)17591-0
- 20. Ghali F, Kang S, Leyden JJ, et al. Changing the face of acne therapy. Cutis 2009; 83 (2 Suppl): 4-15.
- 21. Worret WI, Fluhr JW. Acne therapy with topical benzoyl peroxide, antibiotics and azelaic acid. JDDG 2006; 4: 293-300. doi:10.1111/ j.1610-0387.2006.05931suppl.x